Acetohexamide |
 |
|
| Trade names | Dymelor |
|---|
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
|---|
| MedlinePlus | a602021 |
|---|
| ATC code | |
|---|
|
| Protein binding | 90% |
|---|
|
1-[(4-acetylbenzene)sulfonyl]-3-cyclohexylurea
4-acetyl-N-(cyclohexylcarbamoyl)benzenesulfonamide
|
| CAS Number | |
|---|
| PubChem CID | |
|---|
| IUPHAR/BPS | |
|---|
| DrugBank | |
|---|
| ChemSpider | |
|---|
| UNII | |
|---|
| KEGG | |
|---|
| ChEBI | |
|---|
| ChEMBL | |
|---|
| CompTox Dashboard (EPA) | |
|---|
| ECHA InfoCard | 100.012.301 |
|---|
|
| Formula | C15H20N2O4S |
|---|
| Molar mass | 324.40 g·mol−1 |
|---|
| 3D model (JSmol) | |
|---|
| Melting point | 188 to 190 °C (370 to 374 °F) |
|---|
O=C(NC1CCCCC1)NS(=O)(=O)c2ccc(C(=O)C)cc2
|
InChI=1S/C15H20N2O4S/c1-11(18)12-7-9-14(10-8-12)22(20,21)17-15(19)16-13-5-3-2-4-6-13/h7-10,13H,2-6H2,1H3,(H2,16,17,19) YKey:VGZSUPCWNCWDAN-UHFFFAOYSA-N Y
|
| (verify) |
Acetohexamide (trade name Dymelor) is a first-generation sulfonylurea medication used to treat diabetes mellitus type 2, particularly in people whose diabetes cannot be controlled by diet alone.[1]
Mechanism of action
Acetohexamide binds to an ATP-sensitive K+ (KATP) channel on the cell membrane of pancreatic beta cells. This inhibits the outflux of potassium, which causes the membrane potential to become more positive. This depolarization in turn opens voltage-gated calcium channels. The rise in intracellular calcium leads to increased fusion of insulin granulae with the cell membrane, and therefore increased secretion of insulin.[2]
Risks
Sulfonylureas, especially first-generation sulfonylureas such as Acetohexamide, can cause severe hypoglycemia and increase the risk of adverse cardiovascular events.[3][4]
References
Oral diabetes medication, insulins and insulin analogues, and other drugs used in diabetes (A10) |
|---|
|
|---|
| Fast-acting |
- Insulin aspart
- Insulin glulisine
- Insulin lispro
|
|---|
| Short-acting | |
|---|
| Long-acting |
- Insulin detemir#
- Insulin glargine# (+lixisenatide)
- NPH insulin
- Lente insulin‡
- Ultralente insulin‡
|
|---|
| Ultra-long-acting |
- Insulin degludec# (+insulin aspart, +liraglutide)
- Insulin efsitora†
- Insulin icodec† (+semaglutide)
|
|---|
| Inhalable | |
|---|
| Oral | |
|---|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
|
Non-insulins |
|---|
| Insulin sensitizers | | Biguanides | |
|---|
| TZDs ("-glitazones") and PPAR agonists | |
|---|
| Dual PPAR agonists |
- Aleglitazar†
- Muraglitazar§
- Saroglitazar
- Tesaglitazar§
|
|---|
| Amylin analogues and DACRAs | |
|---|
|
|---|
| Secretagogues | | K+ATP | | Sulfonylureas | |
|---|
| Meglitinides ("-glinides") | |
|---|
|
|---|
| GLP-1 receptor agonists |
- Albiglutide‡
- Danuglipron†
- Dulaglutide
- Exenatide
- Liraglutide
- Lixisenatide
- Orforglipron†
- Semaglutide
- Taspoglutide†
| GLP1 poly-agonist peptides |
- Mazdutide (GLP-1/GCGR)
- Retatrutide§ (GLP-1/GIP/GCGR)
- Tirzepatide (GLP-1/GIP)
|
|---|
|
|---|
| DPP-4 inhibitors ("-gliptins") |
- Alogliptin
- Anagliptin
- Evogliptin
- Garvagliptin
- Gemigliptin
- Gosogliptin
- Linagliptin
- Melogliptin
- Omarigliptin
- Retagliptin
- Saxagliptin
- Sitagliptin
- Teneligliptin
- Trelagliptin
- Vildagliptin
|
|---|
|
|---|
| Other | | Aldose reductase inhibitors | |
|---|
| Alpha-glucosidase inhibitors | |
|---|
| SGLT2 inhibitors ("-gliflozins") |
- Canagliflozin
- Dapagliflozin
- Empagliflozin#
- Ertugliflozin
- Ipragliflozin
- Luseogliflozin
- Remogliflozin§
- Sergliflozin§
- Sotagliflozin
- Tofogliflozin†
- Velagliflozin
|
|---|
| Other | |
|---|
|
|---|
| Combinations |
- Alogliptin/metformin
- Canagliflozin/metformin
- Cagrilintide/semaglutide§
- Dapagliflozin/metformin
- Dapagliflozin/saxagliptin
- Dapagliflozin/saxagliptin/metformin
- Empagliflozin/linagliptin
- Empagliflozin/metformin
- Gemigliptin/rosuvastatin
- Glibenclamide (glyburide)/metformin
- Glimepiride/rosiglitazone
- Linagliptin/metformin
- Metformin/acarbose
- Metformin/ertugliflozin
- Metformin/evogliptin
- Metformin/gemigliptin
- Metformin/repaglinide
- Metformin/sulfonylureas
- Metformin/teneligliptin
- Phenformin/sulfonylureas
- Pioglitazone/alogliptin
- Pioglitazone/glimepiride
- Pioglitazone/metformin
- Pioglitazone/sitagliptin
- Rosiglitazone/metformin
- Saxagliptin/metformin
- Sitagliptin/dapagliflozin
- Sitagliptin/ertugliflozin
- Sitagliptin/metformin
- Sitagliptin/simvastatin
- Vildagliptin/metformin
|
|
|---|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
|